| Recruiting | AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study NCT07326358 | Ruijin Hospital | — |
| Recruiting | Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC NCT06811844 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Enrolling By Invitation | IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma NCT06688175 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Active Not Recruiting | Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma NCT05807880 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma NCT04870905 | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Phase 2 |
| Recruiting | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma NCT06019130 | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Phase 2 |
| Unknown | Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma NCT04446663 | First People's Hospital of Foshan | Phase 2 |
| Unknown | IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. NCT03854838 | Sun Yat-sen University | Phase 2 |
| Unknown | Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma NCT03837808 | Sun Yat-sen University | Phase 3 |
| Active Not Recruiting | GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma NCT03840421 | Sun Yat-sen University | Phase 3 |
| Terminated | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal NCT03769467 | Atara Biotherapeutics | Phase 1 / Phase 2 |
| Unknown | PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma NCT03619824 | Sun Yat-sen University | Phase 2 |
| Unknown | Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma NCT03700476 | Sun Yat-sen University | Phase 3 |
| Active Not Recruiting | PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carci NCT03427827 | Sun Yat-sen University | Phase 3 |
| Unknown | Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carc NCT03093649 | Sun Yat-sen University | N/A |
| Completed | Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma NCT03180476 | Sichuan Cancer Hospital and Research Institute | Phase 2 |
| Completed | A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery NCT03010813 | Chinese University of Hong Kong | N/A |
| Unknown | A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application NCT02980315 | The Second Hospital of Nanjing Medical University | Phase 1 / Phase 2 |
| Terminated | ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Ra NCT02874651 | Sun Yat-sen University | Phase 2 |
| Unknown | Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Car NCT02945878 | Zhejiang Cancer Hospital | — |
| Unknown | A Trial of Endostar in Patients With Carcinoma of the Head and Neck NCT02902432 | China International Medical Foundation | Phase 2 |
| Completed | Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-1 NCT02611960 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for NCT02729324 | Yun-fei Xia | Phase 2 |
| Unknown | Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharynge NCT02735317 | Yun-fei Xia | Phase 2 |
| Unknown | Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal NCT02627807 | Sun Yat-sen University | N/A |
| Unknown | Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With NCT02456506 | Sun Yat-sen University | N/A |
| Completed | Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngea NCT02269943 | Celgene | Phase 2 |
| Completed | The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients NCT02505139 | Sun Yat-sen University | — |
| Unknown | Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal C NCT02211677 | Sun Yat-sen University | — |
| Unknown | Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma NCT02250599 | Sun Yat-sen University | Phase 2 |
| Completed | A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therap NCT02444949 | China Three Gorges University, Yichang, China | Phase 2 |
| Completed | The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT NCT01797900 | Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens NCT01762514 | Sun Yat-sen University | Phase 2 |
| Unknown | Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma NCT01735409 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Completed | Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma NCT01528618 | Sun Yat-sen University | Phase 3 |
| Terminated | Environmental and Genetic Determinants of NPC NCT01257100 | National Cancer Institute (NCI) | — |
| Completed | Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence Afte NCT00747799 | Sun Yat-sen University | Phase 2 |
| Completed | Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma NCT02360501 | Sun Yat-sen University | Phase 2 |
| Completed | Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Pla NCT00630149 | Sun Yat-sen University | Phase 2 |
| Completed | Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma NCT00565448 | Sanofi | Phase 2 |
| Completed | Modified Vaccinia Ankara (MVA) Vaccine Study NCT01256853 | Chinese University of Hong Kong | Phase 1 |
| Unknown | Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal NCT00577057 | Hospital Authority, Hong Kong | N/A |
| Unknown | Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma NCT00363831 | The University of Hong Kong | Phase 2 |
| Terminated | Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal NCT00393224 | National Cancer Institute (NCI) | — |
| Completed | Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma NCT00436800 | Sanofi | Phase 2 |
| Completed | Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer NCT00078494 | National Institutes of Health Clinical Center (CC) | Phase 1 |
| Completed | Intensity Modulated Radiation Therapy for Head and Neck Cancer NCT00188877 | University Health Network, Toronto | Phase 2 |
| Completed | Taxotere + Cisplatin in Nasopharyngeal Carcinoma NCT00436293 | Sanofi | Phase 2 |
| Completed | Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Con NCT00123864 | Alberta Health services | Phase 1 / Phase 2 |
| Terminated | Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcino NCT00563862 | Hospital Authority, Hong Kong | N/A |
| Unknown | Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0) NCT00563927 | Hospital Authority, Hong Kong | N/A |
| Completed | Family Study of Head and Neck Cancers in Taiwan NCT00342147 | National Cancer Institute (NCI) | — |